These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34752263)

  • 1. Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study.
    Ena J; Carretero-Gómez J; Zapatero-Gaviria A; Carrasco-Sánchez FJ; Del Romero-Sánchez M; González-Becerra C; Blazquez-Encinar JC; Iguzquiza-Pellejero MJ; de Escalante Yangüela B; Gómez-Huelgas R;
    Rev Clin Esp (Barc); 2021 Nov; 221(9):517-528. PubMed ID: 34752263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study.
    Ena J; Carretero-Gómez J; Zapatero-Gaviria A; Carrasco Sánchez FJ; Del Romero-Sánchez M; González-Becerra C; Blazquez-Encinar JC; Iguzquiza-Pellejero MJ; de Escalante Yangüela B; Gómez-Huelgas R; ;
    Rev Clin Esp; 2020 Apr; ():. PubMed ID: 32279949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
    Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
    Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
    Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
    Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Type 2 diabetes mellitus: new treatments].
    Ascaso JF
    Med Clin (Barc); 2014 Aug; 143(3):117-23. PubMed ID: 23937815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
    Blood AJ; Chang LS; Hassan S; Chasse J; Stern G; Gabovitch D; Zelle D; Colling C; Aronson SJ; Figueroa C; Collins E; Ruggiero R; Zacherle E; Noone J; Robar C; Plutzky J; Gaziano TA; Cannon CP; Wexler DJ; Scirica BM
    Circulation; 2024 Jun; 149(23):1802-1811. PubMed ID: 38583146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing trends of glucose-lowering drugs in older adults from 2010 to 2021: A population-based study of Northern Italy.
    Foresta A; Succurro E; Baviera M; Macaluso G; Ojeda-Fernández L; Carla Roncaglioni M; Fortino I; Nobili A; Sesti G
    Diabetes Res Clin Pract; 2023 Aug; 202():110742. PubMed ID: 37270072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical profile of patients with type 2 diabetes mellitus treated with sodium- glucose cotransporter-2 inhibitors and experience in real-world clinical practice in Spain.
    Cuatrecasas G; Goñi-Goicoechea F
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():30-34. PubMed ID: 28760223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care.
    O'Hara DV; Janse RJ; Fu EL; Jardine MJ; Carrero JJ
    Diabetes Res Clin Pract; 2024 Jul; 213():111745. PubMed ID: 38876274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study.
    D'Onofrio L; Mignogna C; Carlone A; Bellizzi E; Di Guida M; Moretti C; Zampetti S; Leto G; Maddaloni E; Buzzetti R
    Diabetes Res Clin Pract; 2021 Mar; 173():108681. PubMed ID: 33516784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of newer antidiabetic drugs on cardiovascular prevention and heart failure.
    Rojas-Velázquez JM; Giralt-Herrera A; Leiva-Enríquez J; Leiva-Enríquez J
    Clin Investig Arterioscler; 2021; 33(6):314-322. PubMed ID: 33820673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.
    Battise DM; Olin JL
    J Am Assoc Nurse Pract; 2021 Mar; 33(12):1139-1147. PubMed ID: 33105320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.
    Zhou Z; Zheng M; Zuo Z; Wu T
    ESC Heart Fail; 2024 Jun; 11(3):1647-1656. PubMed ID: 38419382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States.
    Sangha V; Lipska K; Lin Z; Inzucchi SE; McGuire DK; Krumholz HM; Khera R
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008381. PubMed ID: 34779654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.
    Chi C; Snaith J; Gunton JE
    Heart Lung Circ; 2017 Nov; 26(11):1133-1141. PubMed ID: 28473214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.